Literature DB >> 35535098

Nonalcoholic Steatohepatitis, Peroxisome Proliferator-Activated Receptors and Our Good Glitazar: Proof of the Pudding is in the Eating.

Anil C Anand1, Subrata K Acharya2.   

Abstract

Entities:  

Keywords:  AE, adverse event; CAP, controlled attenuation parameter; CDSCO, Central Drugs Standard Control Organisation; LSM, liver stiffness measurement; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; PPAR, peroxisome proliferator–activated receptors; TG, triglyceride

Year:  2022        PMID： 35535098      PMCID： PMC9077217          DOI： 10.1016/j.jceh.2022.01.008

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN： 0973-6883


× No keyword cloud information.
  43 in total

1.  Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes.

Authors:  Isabelle Boutron; Susan Dutton; Philippe Ravaud; Douglas G Altman
Journal:  JAMA       Date:  2010-05-26       Impact factor: 56.272

2.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.

Authors:  Kenneth Cusi; Beverly Orsak; Fernando Bril; Romina Lomonaco; Joan Hecht; Carolina Ortiz-Lopez; Fermin Tio; Jean Hardies; Celia Darland; Nicolas Musi; Amy Webb; Paola Portillo-Sanchez
Journal:  Ann Intern Med       Date:  2016-06-21       Impact factor: 25.391

Review 3.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

4.  Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis.

Authors:  Stergios A Polyzos; Eun Seok Kang; Chrysoula Boutari; Eun-Jung Rhee; Christos S Mantzoros
Journal:  Metabolism       Date:  2020-03-06       Impact factor: 8.694

5.  Lifestyle intervention in non-alcoholic fatty liver disease in Chengyang District, Qingdao, China.

Authors:  Wei-Hui Sun; Ming-Quan Song; Chang-Qing Jiang; Yong-Ning Xin; Jian-Lin Ma; Ying-Xun Liu; Lei Ma; Zhong-Hua Lin; Chang-Yan Li; Ling Liu; Mei Zhang; Lei-Lei Chu; Xiang-Jun Jiang; Qiang Wan; Lin Zhou; Rong Ren; Ling-Fang Meng
Journal:  World J Hepatol       Date:  2012-07-27

6.  Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!

Authors:  Sven Francque
Journal:  Hepatology       Date:  2021-08-30       Impact factor: 17.425

7.  Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.

Authors:  Samer Gawrieh; Mazen Noureddin; Nicole Loo; Rizwana Mohseni; Vivek Awasty; Kenneth Cusi; Kris V Kowdley; Michelle Lai; Eugene Schiff; Deven Parmar; Pankaj Patel; Naga Chalasani
Journal:  Hepatology       Date:  2021-07-19       Impact factor: 17.425

8.  A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).

Authors:  Vikas Pai; A Paneerselvam; Satinath Mukhopadhyay; Anil Bhansali; Dinesh Kamath; V Shankar; Dhiraj Gambhire; Rajendrakumar H Jani; Shashank Joshi; Pankaj Patel
Journal:  J Diabetes Sci Technol       Date:  2014-01-16

9.  Influence and management of conflicts of interest in randomised clinical trials: qualitative interview study.

Authors:  Lasse Østengaard; Andreas Lundh; Tine Tjørnhøj-Thomsen; Suhayb Abdi; Mustafe H A Gelle; Lesley A Stewart; Isabelle Boutron; Asbjørn Hróbjartsson
Journal:  BMJ       Date:  2020-10-27

10.  The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance.

Authors:  Alistair V W Nunn; Jimmy Bell; Philip Barter
Journal:  Nucl Recept       Date:  2007-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.